Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Thermo Fisher Scientific

Explore full profile

Scientific instruments, diagnostics, and life sciences services.

Waltham, United StatesFounded 1956Biotech & Life Sciences
Valuation $284B Market cap · 2026
Revenue $48B Latest reported FY
EBITDA $12B Latest reported FY

About Thermo Fisher Scientific

If you work in a lab, a hospital, or a biotech company, you probably can't get through your day without using a product from Thermo Fisher Scientific. They are the Amazon of the science world, a massive company that provides everything from basic lab supplies to complex analytical instruments and outsourced drug development services. But this giant wasn't built overnight; it's the result of a blockbuster merger between two very different, yet complementary, companies. The story starts on two separate tracks. First, there's Fisher Scientific, founded in 1902 by a 20-year-old engineering graduate from Pittsburgh, Chester G. Fisher. He saw a need to supply the labs of burgeoning industries like steel and created a one-stop shop for scientific tools. Fisher essentially became the definitive catalog and distributor for labs across North America. Decades later, in 1956, Greek immigrant and MIT PhD George Hatsopoulos co-founded Thermo Electron with Peter Nomikos. While Fisher was about distribution, Thermo Electron was about invention. Hatsopoulos was a brilliant engineer focused on applying thermodynamics to create new instruments and technologies. For 50 years, both companies grew independently. Fisher expanded its distribution network, went public in 1965, and became a staple in labs everywhere. Thermo Electron, driven by Hatsopoulos's innovative spirit, developed cutting-edge analytical instruments. The defining moment came in 2006, when the two companies announced a massive $10.6 billion merger. The deal combined Thermo's high-tech instruments with Fisher's vast distribution channels, creating the powerhouse we know today as Thermo Fisher Scientific. Since the merger, the company has been on an acquisition spree, buying dozens of companies to expand its reach into genomics, specialty diagnostics, and biopharma services, including major acquisitions like Life Technologies in 2013 and PPD in 2021. Today, Thermo Fisher Scientific is a dominant force in serving science, a nearly essential partner in global research and healthcare.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1956
Headquarters
Waltham, United States
Listing
IPO 2014
Employees
71,179
Open positions
7,082
Dealroom signal
64.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Medical Data Systems, Genome Engineering, Innovation Radar
Technology
Deep Tech, Nanotech
Business model
Manufacturing
Client focus
b2b
Investment activity
60 companies, latest Oct 2025
Capital deployed
$285M
Preferred round
ACQUISITION

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Feb 2026 $3.8B — Undisclosed ↗
POST IPO DEBT✓Debt Nov 2023 $2.5B — Undisclosed ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $48B +7.4% $12B 26.1% $7.4B 15.5% $1.4B
2025 $45B +3.9% $12B 26.6% $6.7B 15% $1.4B
2024 $43B +0.1% $12B 27.7% $6.3B 14.8% $1.4B
2023 $43B -4.6% $12B 26.9% $1.3B
2022 $45B +14.5% $12B 26.8%
2021 $39B +21.7% $12B 31%
2020 $32B — $10B 31.7%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Thermo Fisher Scientific website traffic

Latest recorded traffic for Thermo Fisher Scientific is 7.4M monthly website visits, up 51% over the last three months. Thermo Fisher Scientific's team grew 0% over the past year.

Latest monthly visits7.4M 3-month web change+51% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ClarioLondon, United KingdomProvides advanced endpoint technology and data solutions to optimize and manage clinical trials for pharmaceutical, biotech, and medical device companies miDiagnosticsLeuven, BelgiumSilicon chip diagnostics for rapid, lab-quality results $132Mvaluation CytoreasonTel Aviv-Yafo, IsraelTurns human clinical data into clear biology, to deliver data-driven target discovery and drug development $320Mvaluation Olink ProteomicsUppsala kommun, SwedenDevelops ground-breaking technologies for biomolecular analysis $3.2Bvaluation CorEvitasWaltham, United StatesCorrona | Syndicated BioPharma Registry Data and Consulting Services $913Mvaluation MarqMetrixSeattle, United StatesYour business an affordable superpower $4Mvaluation The Binding Site GroupBirmingham, United KingdomDevelops, manufactures and distributes specialised immunodiagnostic assays and instrumentation to improve diagnosis and monitoring of blood cancers and immune-system disorders worldwide $2.6Bvaluation IonpathMenlo Park, United StatesEnabling precision medicine through high-definition spatial proteomics $72Mvaluation PharmaFluidicsGhent, BelgiumMicro-chip based columns for analytical liquid chromatography $32Mvaluation CombinatiPalo Alto, United StatesCombinati is a biotechnology company based in Palo Alto $23Mvaluation PPDWilmington, United StatesContract Research Organization (CRO) Clinical Trial Solutions with PPD $17Bvaluation WuXi DiagnosticsPudong, ChinaIntegrated diagnostics platform for multidisciplinary clinical data analysis $600Mvaluation

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Grid

Series A6 investors entered at this stage

Series B and later1 investor entered at this stage

  • Phc
Team profiled 336 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Waltham HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Thermo Fisher Scientific on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Thermo Fisher Scientific’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.